Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2009 Publisher: Sanofi-aventis, One Onslow Street, Guildford, Surrey, GU1 4YS, UK
Ubretid is contraindicated in cases of severe post operative shock, serious circulatory insufficiency, severe constipation, serious spastic and mechanical ileus, asthma and mechanical urinary obstruction.
Caution should be taken in conditions where the potentiation of the effects of acetylcholine is undesirable, eg cardiac dysfunction, bronchospasm, peptic ulcer, oesophagitis, epilepsy and Parkinsonism. The patient should be supervised in the early stages of dosage titration to guard against the possibility of myasthenic crisis or cholinergic crisis.
Use with caution in patients receiving concomitantly drugs acting on the cardiovascular system, e.g. beta blockers, drugs with local anaesthetic properties and muscle relaxants. In myasthenia gravis, where short acting cholinergic drugs are taken concurrently, their dosage should be reduced to the minimum required to control symptoms.
Ubretid should be avoided during pregnancy. No information is available on lactation.
None stated.
The following side effects may occur infrequently: bradycardia, AV block, hypotension, bronchospasm, dyspnoea, increased bronchial secretions, sweating, salivation and lacrimation, muscle twitching, abdominal cramps, diarrhoea, urinary frequency and miosis. These effects of Ubretid may be controlled with atropine, giving 2mg intramuscularly; atropinisation should be maintained for at least 24 hours.
None stated.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
